Moneycontrol PRO

Buy Gland Pharma; target of Rs 3700: Motilal Oswal

Motilal Oswal is bullish on Gland Pharma has recommended buy rating on the stock with a target price of Rs 3700 in its research report dated June 25, 2022.

June 27, 2022 / 02:20 PM IST
 
 
live
  • bselive
  • nselive
Volume
Todays L/H
More

Motilal Oswal's research report on Gland Pharma


After delivering 27% earnings CAGR over FY17-22, GLAND is well-placed to sustain its earnings growth momentum over the next three-to-five years. It has been enhancing its offerings by adding complex products to its portfolio, scaling the product at the global level, expanding capacity to aid manufacturing, as well as increased backward integration. While constraints on availability of certain materials may hinder performance over the near term, GLAND is in good stead for consistent performance over the next three-to-five years. The 40% correction over the past 10-12 months, despite healthy earnings growth, provides sufficient cushion on the valuation front. The stock is trading at 30x FY23E EPS of INR89 and 23x FY24E EPS of INR113.



Outlook


Given its superior business model, consistent compliance,strong return ratios, and surplus cash for inorganic opportunities, we value the stock at 33x 12-month forward earnings to arrive at our TP of INR3,700. We reiterate our Buy rating.

Close

More Info


At 14:14 hrs Gland Pharma was quoting at Rs 2,650.00, up Rs 6.30, or 0.24 percent.


It has touched an intraday high of Rs 2,670.50 and an intraday low of Rs 2,620.85.


It was trading with volumes of 5,498 shares, compared to its thirty day average of 38,402 shares, a decrease of -85.68 percent.


In the previous trading session, the share closed up 1.40 percent or Rs 36.60 at Rs 2,643.70.


The share touched its 52-week high Rs 4,324.65 and 52-week low Rs 2,498.00 on 13 August, 2021 and 20 June, 2022, respectively.


Currently, it is trading 38.72 percent below its 52-week high and 6.08 percent above its 52-week low.


Market capitalisation stands at Rs 43,633.82 crore.


For all recommendations report, click here


Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on moneycontrol.com are their own, and not that of the website or its management. Moneycontrol.com advises users to check with certified experts before taking any investment decisions.

Broker Research
first published: Jun 27, 2022 02:20 pm
Sections
ISO 27001 - BSI Assurance Mark